182 filings
Page 3 of 10
8-K
8gytlkraj06fynvov6q
30 Mar 22
KemPharm Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Corporate Updates
4:36pm
8-K
f1t8a937tey krm
21 Mar 22
KemPharm Announces Full Data Set from Higher-Dose Serdexmethylphenidate (SDX) Phase 1 Clinical Trial
8:49am
8-K
pu5ll7b0y
16 Mar 22
KemPharm team provided development and regulatory services to Corium pursuant to a master development services agreement
8:32am
8-K
n6t1vqevenz
22 Feb 22
Regulation FD Disclosure
9:09am
8-K
f8un9eta xi085e6c7
19 Jan 22
KemPharm Issues Letter to Shareholders Detailing Strategic Focus on CNS/Rare Disease Indications and Updated Clinical Development Strategy
4:27pm
8-K
zwb9adhno7bob3eqzcdf
20 Dec 21
KemPharm, Inc. Announces Authorization of $50 Million Share Repurchase Program
7:43am
8-K
9gpk1xbnqx v8ydgi
14 Dec 21
Regulation FD Disclosure
8:47am
8-K
podt2supucdn
10 Nov 21
KemPharm Reports Third Quarter 2021 Financial Results and Corporate Updates
4:12pm
8-K
0po81b327bvw9 gip
19 Oct 21
KemPharm, Inc. Announces Uplisting to The Nasdaq Global Select Market
9:24am
8-K
eqb9682ie
18 Aug 21
KemPharm Appoints Tamara A. Seymour to Board of Directors
5:01pm
8-K
k6riefw3cue6
12 Aug 21
KemPharm Reports Second Quarter 2021 Financial Results
4:15pm
8-K
bsos9zkgpgtdqrfu0
21 Jul 21
Other Events
8:46am
8-K
zttz 01e89
2 Jul 21
Entry into a Material Definitive Agreement
4:01pm
8-K
6vfzwa3hqu7m f8t46xr
24 Jun 21
Submission of Matters to a Vote of Security Holders
4:14pm
8-K
uc6pwk83pj9at03ik
23 Jun 21
Entry into a Material Definitive Agreement
4:15pm
8-K
f9dn6fxo70zkdlufpqpt
16 Jun 21
KemPharm Issues Letter to Shareholders
9:06am
8-K
hj7z2n2 b3dwjs4lmn
13 May 21
KemPharm Reports First Quarter 2021 Financial Results
4:13pm
8-K
pq1 h8mgea
8 Apr 21
Entry into a Material Definitive Agreement
4:20pm
8-K
r59q54
11 Mar 21
KemPharm Reports Fourth Quarter and Full-Year 2020 Financial Results
4:27pm
8-K
73zs yo68hmnalxa
3 Mar 21
Regulation FD Disclosure
7:58am